OVERSEA CHINESE BANKING Corp Ltd Takes $723,000 Position in IQVIA Holdings Inc. $IQV

OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 3,743 shares of the medical research company’s stock, valued at approximately $723,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Calamos Advisors LLC lifted its position in shares of IQVIA by 268.1% in the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after buying an additional 137,441 shares during the last quarter. Concurrent Investment Advisors LLC increased its holdings in shares of IQVIA by 36.0% during the 4th quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock valued at $2,693,000 after acquiring an additional 3,161 shares during the last quarter. Munich Reinsurance Co Stock Corp in Munich bought a new position in shares of IQVIA in the 4th quarter valued at approximately $3,444,000. Nippon Life Global Investors Americas Inc. raised its stake in shares of IQVIA by 36.6% in the 4th quarter. Nippon Life Global Investors Americas Inc. now owns 79,400 shares of the medical research company’s stock valued at $17,898,000 after acquiring an additional 21,270 shares in the last quarter. Finally, BlackRock Inc. acquired a new stake in IQVIA in the 2nd quarter worth approximately $2,811,292,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 1.6%

IQVIA stock opened at $260.17 on Friday. The business has a 50 day moving average price of $213.32 and a two-hundred day moving average price of $187.52. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $260.40. The stock has a market cap of $42.82 billion, a price-to-earnings ratio of 32.28, a price-to-earnings-growth ratio of 2.17 and a beta of 1.18.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its Board of Directors has approved a share repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

Several brokerages have commented on IQV. Robert W. Baird increased their price target on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Mizuho boosted their price objective on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. JPMorgan Chase & Co. upped their price objective on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Royal Bank Of Canada raised their target price on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Finally, Stifel Nicolaus lifted their target price on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

Insider Buying and Selling at IQVIA

In other news, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares in the company, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 12,913 shares of company stock worth $3,098,793 over the last three months. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.